Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
257M
-
Number of holders
-
1252
-
Total 13F shares, excl. options
-
231M
-
Shares change
-
-1.63M
-
Total reported value, excl. options
-
$80.5B
-
Value change
-
-$566M
-
Put/Call ratio
-
0.96
-
Number of buys
-
589
-
Number of sells
-
-513
-
Price
-
$347.74
Significant Holders of VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) as of Q3 2023
1,401 filings reported holding VRTX - VERTEX PHARMACEUTICALS INC / MA - Common Stock as of Q3 2023.
VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) has 1,252 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 231M shares
of 257M outstanding shares and own 90.2% of the company stock.
Largest 10 shareholders include BlackRock Inc. (22.6M shares), VANGUARD GROUP INC (22M shares), Capital World Investors (18M shares), FMR LLC (14.4M shares), STATE STREET CORP (12M shares), ALLIANCEBERNSTEIN L.P. (7.53M shares), PRICE T ROWE ASSOCIATES INC /MD/ (6.85M shares), WELLINGTON MANAGEMENT GROUP LLP (6.53M shares), JPMORGAN CHASE & CO (6.11M shares), and GEODE CAPITAL MANAGEMENT, LLC (5.6M shares).
This table shows the top 1252 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.